Ekf Diagnostics Regulatory News (EKF)

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Director /PDMR Shareholding

EKF Diagnostics Holdings plc (AIM: EKF) announces that on 21 June 2016, the Company was notified that Harwood Capital LLP ("Harwood") acquired 532,781 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") as investment manager to North Atlantic Smaller Companies Investment Trust PLC ("NAIT"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.

Following the above transaction, which was completed on 17 June 2016 at a price of 11.5 pence per share, NAIT's interest is now in 65,928,103 Ordinary Shares, representing 14.20% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ("Oryx", whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.

The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 105,928,103 Ordinary Shares, representing 22.82% of the Company's issued share capital.